Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Betula occidentalis pollen refers to the pollen derived from the Water Birch tree (Betula occidentalis), a species native to North America. This pollen is recognized as a moderate allergen, capable of inducing allergic reactions such as pollinosis (hay fever) in sensitized individuals. The primary allergenic component identified in birch pollen, including Betula occidentalis, is Bet v 1, a pathogenesis-related protein class 10 (PR-10). Extracts of birch pollen are utilized in medical applications for both diagnostic purposes, such as skin-prick tests, and therapeutic interventions, specifically in allergen immunotherapy to desensitize individuals to birch pollen allergies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Betula occidentalis pollen.